Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancer.
Bundred NJ, Stockton C, Keeley V, Riches K, Ashcroft L, Evans A, Skene A, Purushotham A, Bramley M, Hodgkiss T; Investigators of BEA/PLACE studies. Bundred NJ, et al. Among authors: evans a. Breast Cancer Res Treat. 2015 May;151(1):121-9. doi: 10.1007/s10549-015-3357-8. Epub 2015 Apr 8. Breast Cancer Res Treat. 2015. PMID: 25850535 Clinical Trial.
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039).
Leary A, Evans A, Johnston SR, A'Hern R, Bliss JM, Sahoo R, Detre S, Haynes BP, Hills M, Harper-Wynne C, Bundred N, Coombes G, Smith I, Dowsett M. Leary A, et al. Among authors: a hern r, evans a. Clin Cancer Res. 2015 Jul 1;21(13):2932-40. doi: 10.1158/1078-0432.CCR-14-1428. Epub 2014 Nov 14. Clin Cancer Res. 2015. PMID: 25398453 Clinical Trial.
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Gellert P, Segal CV, Gao Q, López-Knowles E, Martin LA, Dodson A, Li T, Miller CA, Lu C, Mardis ER, Gillman A, Morden J, Graf M, Sidhu K, Evans A, Shere M, Holcombe C, McIntosh SA, Bundred N, Skene A, Maxwell W, Robertson J, Bliss JM, Smith I, Dowsett M; POETIC Trial Management Group and Trialists. Gellert P, et al. Among authors: evans a. Nat Commun. 2016 Nov 9;7:13294. doi: 10.1038/ncomms13294. Nat Commun. 2016. PMID: 27827358 Free PMC article. Clinical Trial.
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Gao Q, López-Knowles E, Cheang MCU, Morden J, Ribas R, Sidhu K, Evans D, Martins V, Dodson A, Skene A, Holcombe C, Mallon E, Evans A, Bliss JM, Robertson J, Smith I, Martin LA, Dowsett M; POETIC Trial Management Group and Trialists. Gao Q, et al. Among authors: evans d, evans a. Breast Cancer Res. 2019 Dec 31;22(1):2. doi: 10.1186/s13058-019-1223-z. Breast Cancer Res. 2019. PMID: 31892336 Free PMC article. Clinical Trial.
Increases in arm volume predict lymphoedema and quality of life deficits after axillary surgery: a prospective cohort study.
Bundred N, Foden P, Todd C, Morris J, Watterson D, Purushotham A, Bramley M, Riches K, Hodgkiss T, Evans A, Skene A, Keeley V; Investigators of BEA/PLACE studies. Bundred N, et al. Among authors: evans a. Br J Cancer. 2020 Jul;123(1):17-25. doi: 10.1038/s41416-020-0844-4. Epub 2020 May 4. Br J Cancer. 2020. PMID: 32362658 Free PMC article.
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer.
Haynes BP, Schuster G, Buus R, Alataki A, Ginsburg O, Quang LH, Han PT, Khoa PH, Van Dinh N, Van To T, Clemons M, Holcombe C, Osborne C, Evans A, Skene A, Sibbering M, Rogers C, Laws S, Noor L, Cheang MCU, Cleator SJ, Smith IE, Dowsett M. Haynes BP, et al. Among authors: evans a. Breast Cancer Res Treat. 2021 Nov;190(2):295-305. doi: 10.1007/s10549-021-06377-3. Epub 2021 Sep 15. Breast Cancer Res Treat. 2021. PMID: 34524591 Free PMC article.
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
Bundred N, Porta N, Brunt AM, Cramer A, Hanby A, Shaaban AM, Rakha EA, Armstrong A, Cutress RI, Dodwell D, Emson MA, Evans A, Hartup SM, Horgan K, Miller SE, McIntosh SA, Morden JP, Naik J, Narayanan S, Ooi J, Skene AI, Cameron DA, Bliss JM. Bundred N, et al. Among authors: evans a. Clin Cancer Res. 2022 Apr 1;28(7):1323-1334. doi: 10.1158/1078-0432.CCR-21-3177. Clin Cancer Res. 2022. PMID: 35165099 Free PMC article. Clinical Trial.
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Bergamino MA, López-Knowles E, Morani G, Tovey H, Kilburn L, Schuster EF, Alataki A, Hills M, Xiao H, Holcombe C, Skene A, Robertson JF, Smith IE, Bliss JM, Dowsett M, Cheang MCU; POETIC investigators. Bergamino MA, et al. EBioMedicine. 2022 Sep;83:104205. doi: 10.1016/j.ebiom.2022.104205. Epub 2022 Aug 16. EBioMedicine. 2022. PMID: 35985932 Free PMC article.
Prevention of lymphoedema after axillary clearance by external compression sleeves PLACE randomised trial results. Effects of high BMI.
Bundred NJ, Barrett E, Todd C, Morris J, Watterson D, Purushotham A, Riches K, Evans A, Skene A, Keeley V; Investigators of BEA/PLACE studies. Bundred NJ, et al. Among authors: evans a. Cancer Med. 2023 Mar;12(5):5506-5516. doi: 10.1002/cam4.5378. Epub 2022 Dec 12. Cancer Med. 2023. PMID: 36507561 Free PMC article. Clinical Trial.
6,140 results